

Practitioner Docket No. MPI00-438P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kapeller-Libermann, Rosana
Application No.: 10/044,205 Group No.: 1642
Filed: October 22, 2001 Examiner: Yu, Misook
For: 69087, 15821, AND 15418, METHODS AND COMPOSITIONS OF HUMAN
PROTEINS AND USES THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the Restriction Requirement (including a species election requirement) dated June 2, 2004, Applicants hereby elect Group I, drawn to SEQ ID NO:1, 3 and nucleic acids encoding SEQ ID NO:2 and variants thereof, vectors, probes, and methods of producing SEQ ID NO:2 protein and variants thereof (claims 1-7, 12 and 18), without prejudice to Applicants' right to pursue the non-elected subject matter in other applications.

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II-XVI in this or subsequent applications.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: July 2, 2004

Sean Hunziker

(type or print name of person certifying)

***WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.**

Practitioner's Docket No. MPI00-438P1RM

In order to be fully responsive, Applicants further elect SEQ ID NO:3, without prejudice to Applicants' right to pursue the non-elected subject matter in the event a generic claim is not found allowable.

Applicants submit herewith a Preliminary Amendment canceling claims 1-23, 39, 42, 45, 47, 65, 71 and 74 and adding new claims 76-82. New claims 76-82 are directed to the subject matter of Group I and are therefore included in Applicants' election. Entry of the Preliminary Amendment prior to examination on the merits is respectfully requested.


This paper is being filed timely and no extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

July 2, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820